PEDIATRICS Vol. 54 No. 1 July 1974, pp. 106-108
This Article
Right arrow Full Text (PDF)
Right arrow P3Rs: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when P3Rs are posted
Right arrow Alert me if a correction is posted
Services
Right arrow E-mail this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My File Cabinet
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via CrossRef
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Fleisher, D. I.
Right arrow Articles by Landau, J. W.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Fleisher, D. I.
Right arrow Articles by Landau, J. W.

Blindness During Diiodohydroxyquin (Diodoquin®) Therapy: A Case Report

David I. Fleisher M.D.1, Robert S. Hepler M.D.1, and Joseph W. Landau M.D.1

1 Departments of Pediatrics, Ophthalmology, and Medicine, UCLA Center for the Health Sciences, Los Angeles, California

A 2frac12-year-old boy developed optic atrophy during an 11-month course of diiodohydroxyquin (Diodoquin) administration. This drug is currently used for several diarrheal conditions. Iodochlorhydroxyquin (Vioform), a congener of Diodoquin, has recently been implicated as the cause of subacute myelo-optic neuropathy (SMON). Attention is drawn to the possible neurotoxic and retinotoxic effects of Diodoquin. Current recommendations concerning the use of halogenated hydroxyquinolines should be reevaluated in light of these data.